EUVIMEDEUVIMED entdecken
Scoping ReviewÜbersichtsarbeitOpen Access · CC BY 4.0

Hereditary Ataxias: From Pathogenesis and Clinical Features to Neuroimaging, Fluid, and Digital Biomarkers—A Scoping Review

Eugenio Bernardi iD, Óscar López-Lombardía, Gonzalo Olmedo-Saura iD, Javier Pagonabarraga iD, Jaime Kulisevsky iD, Jesús Pérez-Pérez iD

International Journal of Molecular Sciences · 15.01.2026 · 27 (2) · 881

DOI: 10.3390/ijms27020881 ↗

Kurz gefasst

Scoping Review in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.01.2026. Verfasst von Eugenio Bernardi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Movement Disorders Unit, Neurology Department, Sant Pau Hospital, 08025 Barcelona, Spain. Hauptthemen laut MEDLINE: Biomarkers, Neuroimaging, Spinocerebellar Degenerations. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 192 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hereditary ataxias are a heterogeneous group of disorders with overlapping clinical presentations but diverse genetic and molecular etiologies. Biomarkers are increasingly essential to improve diagnosis, refine prognosis, and accelerate the development of targeted therapies. Following PRISMA-ScR guidelines, we conducted a scoping review of PubMed and complementary sources (2010–2025) to map and describe the current landscape of genetic, imaging, fluid, electrophysiological, and digital biomarkers across the most prevalent hereditary ataxias, including SCA1, SCA2, SCA3, SCA6, SCA7, SCA17, SCA27B, dentatorubral–pallidoluysian atrophy (DRPLA), Friedreich’s ataxia (FRDA), RFC1-related ataxia (CANVAS), SPG7, and fragile X-associated tremor/ataxia syndrome (FXTAS). Eligible evidence encompassed observational cohorts, clinical trials, case series, and case reports providing primary biomarker data, with the objective of characterizing evidence breadth and identifying knowledge gaps rather than assessing comparative effectiveness. Across modalities, converging evidence highlights subtype-specific biomarker signatures. MRI volumetry, DTI, and FDG-PET map characteristic neurodegeneration patterns. Fluid biomarkers such as neurofilament light chain are informative across several SCAs and FRDA, while frataxin levels constitute robust endpoints in FRDA trials. Pathology-specific biomarkers such as ataxin-3 are advancing as tools for target engagement and may generalize to future gene-lowering strategies. Electrophysiological and oculographic measures show sensitivity for early disease detection, and wearable technologies are emerging as scalable tools for longitudinal monitoring. This scoping review synthesizes the heterogeneous evidence on hereditary ataxia biomarkers, highlighting multimodal frameworks that link molecular mechanisms with clinical endpoints. Mapping current approaches also reveals substantial variability and gaps across diseases and modalities, underscoring the need for harmonized validation in international multicenter cohorts and systematic integration into future clinical trials to advance precision medicine in hereditary ataxias.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersNeuroimagingSpinocerebellar DegenerationsHumansFriedreich Ataxia

Stichwörter der Autor:innen

CANVASFDG-PETFXTASFriedreich’s ataxiaMRI biomarkerbiomarkercerebellar ataxiagenetic ataxiahereditary ataxianeurofilament light chainspinocerebellar ataxia

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Movement Disorders Unit, Neurology Department, Sant Pau Hospital, 08025 Barcelona, Spain.
  • Medicine Department, Autonomous University of Barcelona (UAB), 08193 Barcelona, Spain.
  • Center for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, 28029 Madrid, Spain.
  • Sant Pau Biomedical Research Institute (IIB-Sant Pau), 08041 Barcelona, Spain.

ORCID-Profile: Eugenio Bernardi, Gonzalo Olmedo-Saura, Javier Pagonabarraga, Jaime Kulisevsky, Jesús Pérez-Pérez

Zitieren

APA

Bernardi, E., López-Lombardía, Ó., Olmedo-Saura, G., Pagonabarraga, J., Kulisevsky, J., & Pérez-Pérez, J. (2026). Hereditary Ataxias: From Pathogenesis and Clinical Features to Neuroimaging, Fluid, and Digital Biomarkers—A Scoping Review. International Journal of Molecular Sciences, 27(2), 881. https://doi.org/10.3390/ijms27020881

Vancouver

Bernardi E, López-Lombardía Ó, Olmedo-Saura G, Pagonabarraga J, Kulisevsky J, Pérez-Pérez J. Hereditary Ataxias: From Pathogenesis and Clinical Features to Neuroimaging, Fluid, and Digital Biomarkers—A Scoping Review. International Journal of Molecular Sciences. 2026;27(2):881. doi:10.3390/ijms27020881

BibTeX
@article{Bernardi2026,
  author = {Bernardi, Eugenio and López-Lombardía, Óscar and Olmedo-Saura, Gonzalo and Pagonabarraga, Javier and Kulisevsky, Jaime and Pérez-Pérez, Jesús},
  title = {Hereditary Ataxias: From Pathogenesis and Clinical Features to Neuroimaging, Fluid, and Digital Biomarkers—A Scoping Review},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {2},
  pages = {881},
  doi = {10.3390/ijms27020881}
}
Kostenlos starten →